CTNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Contineum Therapeutics Inc (CTNM) does not present a strong buy opportunity for a beginner investor with a long-term strategy. The technical indicators, options data, and financial performance do not provide compelling reasons to invest at this time. The stock lacks positive momentum, and there are no significant catalysts or trading signals to suggest immediate upside potential.
The MACD is negatively expanding (-0.32), indicating bearish momentum. RSI is at 27.705, suggesting the stock is approaching oversold territory but not yet providing a clear buy signal. Moving averages are converging, showing no strong trend. The stock is trading below the pivot level of 13.395, with key support at 12.163 and resistance at 14.626.
NULL identified. No recent news or significant events to drive the stock upward. Analyst Charles Moore raised the price target to $20, citing clinical catalysts in 2026, but these are long-term and do not impact the near-term outlook.
Morgan Stanley downgraded the stock to Equal Weight, citing disappointing Phase 2 study results and a lack of near-term catalysts. The financials show negative net income (-$15.16M) and declining EPS (-12.50% YoY). Options data reflects bearish sentiment, and technical indicators suggest downward pressure.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$15.16M, though this improved by 4.06% YoY. EPS dropped by 12.50% YoY to -0.49. Gross margin remains at 0%, indicating no profitability.
Analyst sentiment is mixed. Baird raised the price target to $20, citing potential long-term catalysts, while Morgan Stanley downgraded the stock to Equal Weight with a reduced price target of $14, citing disappointing clinical trial results and lack of near-term growth drivers.
